期刊文献+

左卡尼汀与2型糖尿病 被引量:1

Effects of L--carnitine and type 2 diabetes mellitus
下载PDF
导出
摘要 目前2型糖屎病被认为是一种进展性疾病。2型糖尿病患者的非药物治疗是以医学营养疗法和加强体力活动为基础的。如果通过加入药物的膳食补充能有效地增强机体胰岛素的敏感性(如LC),那么这对于辅助治疗糖尿病来说是一种非常诱人的新方法。基于上述的研究结果,推测LC补充会减少脂毒性物质的代谢,从而改善线粒体功能和胰岛素信号转导。下一步,需要进行更大规模的临床随机对照实验及基础研究,使得我们能深入的了解,供过于求的脂质通过何种机制导致骨骼肌胰岛素抵抗,以及LC补充如何改变脂肪酸代谢、胰岛素作用和线粒体功能。 Current type 2 diabetes is considered to be a progressive disease. Type 2 diabetes mellitus patients with non drug treatment is to strengthen the medical nutrition therapy and physical activity based. If by adding drug dietary supplements can effectively enhance the insulin sensitivity ( such as LC ), then for the adjuvant treatment of diabetes is a very attractive new method. Based on the above results, suggesting that LC supplement will reduce lipotoxicity sub stance metabolism, thereby improving mitochondrial function and insulin signal transduction. The next step, need to undertake more large--scale randomized controlled experiment and basic research, we can make in--depth understanding, pile up in excess of requirement lipid mechanism through which leads to insulin resistance in skeletal muscle, as well as LC how changes in fatty acid metabolism, insulin action and mitoehondrial function.
出处 《成都医学院学报》 CAS 2012年第B09期16-17,共2页 Journal of Chengdu Medical College
基金 内蒙古民族大学科学技术研究课题,项目编号:MDX2008095
关键词 左卡尼汀 糖尿病 胰岛素抵抗 乙酰辅酶A Carnitine diabetes insulin resistance acetyl coenzyme A
  • 相关文献

参考文献12

  • 1Boden G, Shulman GI. Free fatty acids in obesity and type 2 diabetes: defining their role in the development of insulin resistance and beta--cell dysfunction. Eur J Clin Invest 2002; 32(Suppl 3) : 14-23.
  • 2McGarry JD. Banting lecture 2001: dysregulation of fatty acid metabo- lism in the etiology of type 2 diabetes. Diabetes 2002351:7 - 18.
  • 3Shulman GI. Cellular mechanisms of insulin resistance. J Clin Invest 2000, 106:171 - 176.
  • 4Unger RH. Lipotoxie diseases. AnnuRevMed 2002 ; 53 : 319 - 336.
  • 5ArduiniA, BonominiM, SavicaV, AmatoA, ZammitV. Carnitine In meta- bolic disease: potential for pharmacological intervention. Pharmaeol Ther 2008;120:149-56.
  • 6Ferrannini E, Buzzigoli G, Bevilacqua S, Boni C, Del Chiaro D, Oleggini M, et al. Interaction of earnitine with insulin--stimulated glucose metabo- lism in humans. AmJ Physiol 1988, 255: E946 - E952.
  • 7Stephens FB, Constantin--Teodosiu D, Greenhaff PL. New insights concerning the role ofcarnitine in the regulation of fuel metabolism in skeletal muscle. J Physiol 2007, 581: 431 - 444.
  • 8Mingrone G, Greco AV, Capristo E, Benedetti G, Giancaterini A, De Gaetano A, et al. L--earnitine improves glucose disposal in type 2 dia- betic patients. J Am Coil Nutr 1999, 18:77 - 82.
  • 9Capaldo B, Napoli R, Di Bonito P, Albano G, Sacca L. Carnitine im- proves peripheral glucose disposal in non- insulin- dependent diabetic patients. Diabetes Res Clin Pract 1991,14:191 - 195.
  • 10DeGaetano A, Mingrone G, Castagneto M, Calvani M. Carnitine increa- ses glucose disposal in humans. J Am Coll Nutr 1999,18:289 - 295.

同被引文献5

引证文献1

二级引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部